Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03824392
Other study ID # ATYR1923-C-002
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 29, 2019
Est. completion date June 29, 2021

Study information

Verified date June 2023
Source aTyr Pharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date June 29, 2021
Est. primary completion date June 29, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Key Inclusion Criteria: - Diagnosis of pulmonary sarcoidosis for =6 months (cutaneous and ocular involvement allowed), defined as: - Histologically proven diagnosis of sarcoidosis by bronchoscopy, biopsy (any organ) or bronchioalveolar lavage - Parenchymal lung involvement by historical radiological evidence - Must have symptomatic and/or active pulmonary sarcoidosis as evidenced by: - Modified Medical Research Council Dyspnea Scale grade of >= 1; and - Forced vital capacity =50%; and - Receiving treatment with 10 to 25 mg/day of oral prednisone (or equivalent), at a stable dose for =4 weeks prior to Day 1, and capable of undergoing the protocol-specified steroid taper regimen. - Body weight =45 kg and <160 kg. Key Exclusion Criteria: - Current disease presentation consistent with Lofgren's syndrome. - History of severe allergic or anaphylactic reactions to therapeutic proteins or known sensitivity to efzofitimod or to its inactive components (L-histidine, sodium chloride, sucrose, L-methionine, and polysorbate-20). - Treatment with biological immunomodulators such as tumor necrosis factor-alpha inhibitors. - Current evidence of clinically significant cardiovascular, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires other treatment. - Clinically significant pulmonary hypertension requiring vasodilator treatment. - Any history of tuberculosis or evidence of active systemic non-tuberculosis fungal or mycobacterial infection within 1 year of Screening. - History of clinically significant cardiac, neurological, gastrointestinal, and/or renal manifestations of sarcoidosis. - Any condition that necessitated hospitalization within the 3 months prior to Day 1 or is likely to require so during the study. - Participation in another clinical study of an investigational agent or device within 3 months (small molecules) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer. - History of or positive results of screening for hepatitis B, hepatitis C or human immunodeficiency virus. - Is an active, heavy smoker of tobacco/nicotine-containing products (defined as >20 cigarettes/day or e-cigarette equivalent). - Active substance abuse or history of substance abuse within the 12 months prior to Screening. - Participant has received a live vaccination within 8 weeks before Day 1 or inoculation with a live vaccine is planned during study participation. - Positive for Jo-1 antibodies (Ab) at Screening, or past history of Jo-1 Ab positivity. - Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Efzofitimod 1.0 mg/kg or Placebo
Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 3.0 mg/kg or Placebo
Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 5.0 mg/kg or Placebo
Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States University of Alabama Birmingham Alabama
United States Medical University of South Carolina Charleston South Carolina
United States aTyr Investigative Site Chicago Illinois
United States Northwestern University Chicago Illinois
United States University of Cincinnati Cincinnati Ohio
United States Cleveland Clinic Cleveland Ohio
United States UT Southwestern Medical Center Dallas Texas
United States National Jewish Health Denver Colorado
United States Inova Fairfax Medical Center Falls Church Virginia
United States East Carolina University Greenville North Carolina
United States University of Iowa Iowa City Iowa
United States University of Louisville Louisville Kentucky
United States aTyr Investigative Site Miami Florida
United States aTyr Investigative Site Northridge California

Sponsors (2)

Lead Sponsor Collaborator
aTyr Pharma, Inc. Foundation for Sarcoidosis Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs were defined as any adverse event or worsening of an existing condition after initiation of the investigational product and through 30 days after the participant's last study visit (study completion or early termination). SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. Baseline up to Week 24
Secondary Time-adjusted Area Under the Curve (AUC) of Background Oral Corticosteroid (OCS) Usage Over Study Period Time adjusted AUC is a measure of steroid burden and approximates the average daily OCS dose (mg/day) post-baseline for each participant. Time adjusted AUC was calculated by AUC divided by the number of days between first and last day of time interval of interest. Baseline up to Week 24 (Day 1 to End of Dosing Period)
Secondary Number of Participants Who Achieved and Maintained The Targeted Tapered Dose of Prednisone 5 mg/Day (or Equivalent) Baseline up to Week 24
Secondary Number of Participants With Positive Anti-Drug Antibodies (Anti-Efzofitimod) The number of all participants having drug reactive antibodies at any point in time (efzofitimod and placebo matched to efzofitimod) have been reported. Baseline up to Week 24
Secondary Number of Participants With at Least One Positive Anti-Jo-1 Antibodies Titers Baseline up to Week 24
See also
  Status Clinical Trial Phase
Completed NCT04064242 - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Phase 2
Terminated NCT00262132 - Mycophenolate for Pulmonary Sarcoidosis Phase 3
Recruiting NCT05415137 - Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Phase 3
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT04318392 - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting NCT03755245 - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis N/A
Completed NCT01587001 - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis N/A
Recruiting NCT05890729 - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 1/Phase 2
Recruiting NCT02824419 - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Phase 2/Phase 3
Recruiting NCT06205121 - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis Phase 2
Completed NCT02200146 - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Phase 3
Terminated NCT01732211 - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Phase 2
Enrolling by invitation NCT06169397 - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2
Active, not recruiting NCT05368883 - Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis N/A
Not yet recruiting NCT05247554 - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Phase 3
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting NCT02188017 - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Phase 4
Recruiting NCT06113991 - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed NCT01169038 - Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Phase 1
Completed NCT00701207 - Study of Nicotine Patches in Patients With Sarcoidosis Early Phase 1